Undervalued Biotechnology Stocks on NAS April 2025

April 20, 2025

Biotechnology

Biotechnology and Biopharmaceutical companies are engaged in research, discovery, development, and production of innovative drug and drug-related technologies.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Biotechnology stocks

Stocks in this category are held primarily for capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
RAPT RAPT Therapeutics 0.79 3.18 302.69 1083944 32 0.00 0.0
RNAZ TransCode Therapeutics 0.27 1.03 279.48 14459315 0 0.00 0.0
BIVI BioVie 0.84 2.76 228.15 223793 13 0.00 0.0
ACET Adicet Bio 0.53 1.63 210.20 556045 46 0.00 0.0
FGEN FibroGen 0.29 0.87 205.22 1201530 29 0.00 0.0
GLMD Galmed Pharmaceuticals 1.38 4.11 197.67 142818 1 0.00 0.0
CYCC Cyclacel Pharmaceuticals 0.23 0.63 180.73 173226 1 0.00 0.0
IOVA Iovance Biotherapeutics 3.06 8.42 175.15 9628149 887 0.00 0.0
OVID Ovid Therapeutics 0.29 0.78 171.22 444658 20 0.00 0.0
CRBU Caribou Biosciences 0.73 1.95 165.06 1052944 66 0.00 0.0
All data provided as at market close April 16, 2025.

Company Details

RAPT Therapeutics

RAPT:NAS

Close Price

0.79

Our Valuation

3.18

% Difference

302.69

Market Cap ($M)

32

P/E Ratio

0.0

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases.

Access the stockcalc valuation


TransCode Therapeutics

RNAZ:NAS

Close Price

0.27

Our Valuation

1.03

% Difference

279.48

Market Cap ($M)

0

P/E Ratio

0.0

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis.

Access the stockcalc valuation


BioVie

BIVI:NAS

Close Price

0.84

Our Valuation

2.76

% Difference

228.15

Market Cap ($M)

13

P/E Ratio

0.0

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease.

Access the stockcalc valuation


Adicet Bio

ACET:NAS

Close Price

0.53

Our Valuation

1.63

% Difference

210.20

Market Cap ($M)

46

P/E Ratio

0.0

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

FibroGen

FGEN:NAS

Close Price

0.29

Our Valuation

0.87

% Difference

205.22

Market Cap ($M)

29

P/E Ratio

0.0

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements.

Access the stockcalc valuation


Galmed Pharmaceuticals

GLMD:NAS

Close Price

1.38

Our Valuation

4.11

% Difference

197.67

Market Cap ($M)

1

P/E Ratio

0.0

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis.

Access the stockcalc valuation


Cyclacel Pharmaceuticals

CYCC:NAS

Close Price

0.23

Our Valuation

0.63

% Difference

180.73

Market Cap ($M)

1

P/E Ratio

0.0

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.

Access the stockcalc valuation


Iovance Biotherapeutics

IOVA:NAS

Close Price

3.06

Our Valuation

8.42

% Difference

175.15

Market Cap ($M)

887

P/E Ratio

0.0

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer.

Access the stockcalc valuation


Ovid Therapeutics

OVID:NAS

Close Price

0.29

Our Valuation

0.78

% Difference

171.22

Market Cap ($M)

20

P/E Ratio

0.0

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures.

Access the stockcalc valuation


Caribou Biosciences

CRBU:NAS

Close Price

0.73

Our Valuation

1.95

% Difference

165.06

Market Cap ($M)

66

P/E Ratio

0.0

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
RAPT Therapeutics and TransCode Therapeutics are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-april-2025
RAPT Therapeutics $RAPT and TransCode Therapeutics $RNAZ are the most undervalued Biotechnology stocks on the #NAS. See the full list: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-april-2025
RAPT Therapeutics and TransCode Therapeutics are the most undervalued Biotechnology stocks on the NAS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-biotechnology-stocks-nas-april-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.